You are currently viewing the editor's summary.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
All roads lead to antitumor immunity
Immune checkpoint blockade immunotherapy for cancer has been achieving increasing prominence in recent years, but, unfortunately, it still only works for a subset of patients and tumor types. Wang et al. found that higher expression of lysine demethylase KDM5A in tumors correlates with their responses to immune checkpoint inhibition. The authors then found a way to take advantage of this mechanism using a compound that increased both KDM5A and a key immune checkpoint protein. At the same time, this compound also activated Toll-like receptor signaling, further stimulating antitumor immunity in multiple mouse models.
- Copyright © 2020 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works
This is an article distributed under the terms of the Science Journals Default License.